These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32072585)

  • 41. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.
    Nakayama H; Tsukamoto K
    Invest New Drugs; 2018 Aug; 36(4):702-708. PubMed ID: 29667133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bridging the new drug access gap between China and the United States and its related policies.
    Zhu X; Chen Y
    Front Pharmacol; 2023; 14():1296737. PubMed ID: 38259295
    [No Abstract]   [Full Text] [Related]  

  • 44. Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea.
    Jeong H; Purja S; Kim E
    Gene Ther; 2024 May; 31(5-6):242-254. PubMed ID: 38200263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of the success rates of new drug development in Japan and the lag behind the US.
    Hirai Y; Yamanaka Y; Kusama M; Ishibashi T; Sugiyama Y; Ono S
    Health Policy; 2012 Mar; 104(3):241-6. PubMed ID: 22172246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delays in neurological drug development in Japan.
    Shimazawa R; Ikeda M
    Intern Med; 2011; 50(15):1565-8. PubMed ID: 21804282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Entry Lag of Innovative Drugs in Russia, 2010-2019.
    Chaplenko A; Gildeeva G; Vlassov V
    Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34064608
    [No Abstract]   [Full Text] [Related]  

  • 49. Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies.
    Hidaka M; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2024 Jul; 58(4):714-720. PubMed ID: 38575785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The year's new drugs & biologics, 2011.
    Graul AI; Cruces E; Dulsat C; Arias E; Stringer M
    Drugs Today (Barc); 2012 Jan; 48(1):33-77. PubMed ID: 22384459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China.
    Peng F; Zheng H
    Ther Innov Regul Sci; 2023 Nov; 57(6):1314-1321. PubMed ID: 37651044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan.
    Tanaka A; Suzuki H; Toyoshima S; Nagai N
    Ther Innov Regul Sci; 2022 Jan; 56(1):85-95. PubMed ID: 34406635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways.
    Kim S; Cho H; Kim J; Lee K; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):119-126. PubMed ID: 32308058
    [No Abstract]   [Full Text] [Related]  

  • 54. Exploring differences in drug doses between Japan and Western countries.
    Arnold FL; Kusama M; Ono S
    Clin Pharmacol Ther; 2010 Jun; 87(6):714-20. PubMed ID: 20410879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
    Noguchi A; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies.
    Han Y; Jiang R; Li J; Wang Y; Shao R; Xie J
    Clin Pharmacol Ther; 2024 Jun; 115(6):1400-1407. PubMed ID: 38429944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Participation to international registration trials--from the investigator's standpoint].
    Ohtsu A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utilization of the Bridging Strategy for the Development of New Drugs in Oncology to Avoid Drug Lag.
    Kogure S; Koyama N; Hidaka S
    J Clin Pharmacol; 2017 Nov; 57(11):1479-1490. PubMed ID: 28628225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.